European Oncology Clinical Trials Have Declined
A new report shows fewer cancer research studies, potentially limiting treatment access for patients.
Updated on Oct. 8, 2026 in Cancer
Live Poll
Should the European Union dedicate more of its competitiveness funding to cancer research?
The European Cancer Organisation released a report highlighting a significant drop in oncology clinical trials across the region. With cancer projected to become the leading cause of death in Europe by 2035, experts worry this trend could impact patient care.
Why it matters
Clinical trials often serve as a vital first line of treatment for patients with rare or advanced cancer cases. A decline in these trials may reduce access to innovative therapies that could otherwise extend or improve quality of life.
The European Cancer Organisation report shows Europe's share of global oncology clinical trials dropped to 21% in 2023 from over 40% in 2008. Additionally, the number of trials started by European companies fell by 8% between 2008 and 2023.
The players
European Cancer Organisation
An entity representing cancer professionals and patient groups that advocates for improved access to treatment.
The details
The decline is attributed in part to complex, overlapping regulatory requirements that complicate study implementation. Specifically, differing national interpretations of the General Data Protection Regulation and clinical trial and medical device rules create barriers for researchers. These administrative hurdles make it increasingly difficult to launch and manage multi-center trials across the European Union.
Timeline
In 2008, Europe accounted for over 40% of global clinical trials.
Between 2008 and 2023, European oncology trials initiated by companies fell by 8%.
In 2023, Europe's share of global oncology trials stood at 21%.
The European Cancer Organisation published its report in October 2026.
Cancer is projected to become the leading cause of death in Europe by 2035.
Health Landscape
This report highlights how regulatory friction, including the General Data Protection Regulation, is impacting the European research landscape. It sits in contrast to global efforts to accelerate oncology advancements as cancer rates rise.
Patients with rare or advanced cancer should talk to their physician about the availability of clinical trials in their area. Access to these experimental studies can be a critical step in managing complex diagnoses when standard treatments are insufficient.
The takeaway
The decline in clinical trials underscores the growing challenge of ensuring patient access to life-saving innovation. If you are exploring treatment options, consider discussing the availability of clinical trials with your oncologist to understand what research programs might be accessible.
Further reading
For more on the latest research and policy trends, visit our section on Cancer.
Source note: This article includes information reported by Euractiv DE.
Live Poll
Should the European Union dedicate more of its competitiveness funding to cancer research?
